<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01320761</url>
  </required_header>
  <id_info>
    <org_study_id>ATX-101-10-19</org_study_id>
    <nct_id>NCT01320761</nct_id>
  </id_info>
  <brief_title>A Study to Assess Injection Comfort of Two Formulations of ATX-101</brief_title>
  <official_title>A Study to Assess Injection Comfort of Two Formulations of ATX-101 (Sodium Deoxycholate Injection) Following Subcutaneous Administration in the Submental Area</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kythera Biopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kythera Biopharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety and injection comfort of ATX-101-BA versus ATX-101-BA-free immediately&#xD;
      following injection and at regular intervals up to 24-hours post-injection following&#xD;
      subcutaneous administration into the submental area.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comfort measure</measure>
    <time_frame>up to 24 hours after treatment</time_frame>
    <description>The primary measure of comfort is the pain comparison scale between ATX-101-BA and ATX-101-BA-free at the time of injection using the pain comparison scale and the VAS pain rating scale.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Group 1A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Left side injected first:&#xD;
Left submental - ATX-101-BA Right submental - ATX-101-BA-free</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Right side injected first:&#xD;
Left submental - ATX-101-BA Right submental - ATX-101-BA-free</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Left side injected first:&#xD;
Left submental - ATX-101-BA-free Right submental - ATX-101-BA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Right side injected first:&#xD;
Left submental - ATX-101-BA-free Right submental - ATX-101-BA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATX-101-BA-free</intervention_name>
    <description>ATX-101-BA-free</description>
    <arm_group_label>Group 1A</arm_group_label>
    <arm_group_label>Group 1B</arm_group_label>
    <arm_group_label>Group 2A</arm_group_label>
    <arm_group_label>Group 2B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATX-101-BA</intervention_name>
    <description>ATX-101-BA</description>
    <arm_group_label>Group 1A</arm_group_label>
    <arm_group_label>Group 1B</arm_group_label>
    <arm_group_label>Group 2A</arm_group_label>
    <arm_group_label>Group 2B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Presence of submental fat graded by the investigator as 2, 3, or 4 using the CR-SMFRS&#xD;
             (Appendix B).&#xD;
&#xD;
          2. Sufficient and symmetrical submental fat such that the protocol-specified number of&#xD;
             injections can be safely administered on both the right and left side.&#xD;
&#xD;
          3. No difference in perception or sensitivity (pain or otherwise) between left and right&#xD;
             sides of the submental area.&#xD;
&#xD;
          4. Abstinence from alcohol for at least 6 hours prior to both the Baseline and 24-hour&#xD;
             visits.&#xD;
&#xD;
          5. Males or nonpregnant, nonlactating females who are aged 18 to 65 years, inclusive, on&#xD;
             Baseline date.&#xD;
&#xD;
          6. Females of child-bearing potential must have a negative urine human chorionic&#xD;
             gonadotropin (hCG) test result from a sample obtained during the screening period.&#xD;
             Females of childbearing potential must agree to practice adequate contraception, in&#xD;
             the judgment of the investigator, during the course of the trial (including&#xD;
             post-screening).&#xD;
&#xD;
          7. The subject is expected to comply with and understand the visit schedule and all of&#xD;
             the protocol-specified tests and procedures.&#xD;
&#xD;
          8. The subject is medically able to undergo the administration of study material as&#xD;
             determined by clinical and laboratory evaluations obtained within 14 days before&#xD;
             dosing with study material for which the investigator identifies no clinically&#xD;
             significant abnormality.&#xD;
&#xD;
          9. Signed informed consent obtained before any study-specific procedure is conducted.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of any intervention (e.g., liposuction) or trauma associated with the chin or&#xD;
             neck areas, which in the judgment of the investigator, may affect subject safety or&#xD;
             other evaluations of treatment.&#xD;
&#xD;
          2. Evidence of any cause of enlargement in the submental area (e.g., thyroid enlargement,&#xD;
             cervical adenopathy) other than localized submental fat.&#xD;
&#xD;
          3. Any medical condition (e.g., respiratory, cardiovascular, hepatic, neurological&#xD;
             disease, uncontrolled hypertension, thyroid dysfunction), that would interfere with&#xD;
             the assessment of safety in this trial or would compromise the ability of the subject&#xD;
             to undergo study procedures or to give informed consent.&#xD;
&#xD;
          4. Any cognitive impairment that, in the Investigator's opinion, would preclude study&#xD;
             participation or compliance with protocol-specified procedures.&#xD;
&#xD;
          5. Treatment with analgesics or other agents that could affect the pain response,&#xD;
             including but not limited to acetaminophen or ibuprofen taken within 1 day prior to&#xD;
             Baseline; additionally, narcotic analgesics, tranquilizers, hypnotics, sedatives, or&#xD;
             opiates within 7 days prior to Baseline.&#xD;
&#xD;
          6. Treatment of the chin or SMF with injectable steroids within 90 days prior to&#xD;
             Baseline.&#xD;
&#xD;
          7. Participation in a pain study within 6 months prior to Baseline.&#xD;
&#xD;
          8. History of chronic pain and/or a history of chronic analgesic or tranquilizer use&#xD;
             within 90 days prior to Baseline.&#xD;
&#xD;
          9. Any anticipated need for agents with anticoagulative effects (e.g., aspirin,&#xD;
             ibuprofen, warfarin, heparin) during the course of the trial.&#xD;
&#xD;
         10. Treatment with oral anticoagulants (e.g., aspirin, warfarin) within 10 days prior to&#xD;
             Baseline.&#xD;
&#xD;
         11. Treatment with topical agents to the submental or neck area, including but not limited&#xD;
             to creams or ointments used to treat dermatologic conditions (e.g., steroids,&#xD;
             capsaicin, retinoids, fluorouracil) within 7 days prior to Baseline.&#xD;
&#xD;
         12. Treatment with radio frequency, laser procedures, chemical peel, or dermal fillers in&#xD;
             the neck or chin area within 12 months before dosing or botulinum toxin injections&#xD;
             within 6 months prior to Baseline.&#xD;
&#xD;
         13. Previous enrollment into this trial or treatment with ATX-101 or agents containing&#xD;
             deoxycholate.&#xD;
&#xD;
         14. Treatment with an investigational agent within 28 days prior to Baseline.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patricia Walker, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Kythera Biopharmaceuticals, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Joel Schlessinger, M.D.</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeffrey M. Adelglass, M.D.</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <study_first_submitted>March 18, 2011</study_first_submitted>
  <study_first_submitted_qc>March 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2011</study_first_posted>
  <last_update_submitted>March 21, 2011</last_update_submitted>
  <last_update_submitted_qc>March 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 22, 2011</last_update_posted>
  <responsible_party>
    <name_title>Daniel R. Lee, M.S., Director, Clinical Affairs</name_title>
    <organization>Kythera Biopharmaceuticals, Inc</organization>
  </responsible_party>
  <keyword>Formulation Comparison</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

